# Westpark Capital

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/westpark-capital
Canonical HTML page: https://getbiobrief.com/entity/westpark-capital

## Recent coverage (1 stories)

### TLPH Upgrade: 113% Upside to $3 Target Sparks Biotech Interest
2026-08-11 12:29:49 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Analyst action pushes Talphera into the spotlight as a deeply undervalued biotech, with a $3.00 average target offering over 100% upside. Recent earnings beat and institutional buying add to the narrative. Two buy initiations from specialized firms highlight confidence in the pain management pipeline.
Full story: https://getbiobrief.com/story/talphera-upgrade-biotech-113-upside-target

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.